Seven measurements of the effect of clenbuterol on basal nitrogen excretion (UN,), and protein turnover were made in six female sheep. The sheep were sustained by the intraruminal infusion of energy as volatile fatty acids to provide maintenance, but given no protein (N-free) for 12 d (6 d control, 6 d clenbuterol). Clenbuterol reduced UN, by 20%, but only on day 2 of the 6 d subperiod. Protein flux (equivalent to degradation on N-free nutrition), measured on day 6 by the irreversible loss of leucine was significantly increased (12 %) by clenbuterol. Amino-N oxidation measured by N excretion was unchanged and, therefore, protein synthesis was also increased. During the 12 d N-free period, the recovery of urinary total N (Kjeldahl) as the sum of urea, ammonia, creatinine and purine derivatives, declined from 87.7 to 74.2 %. The form of this missing N was not identified. The effect of clenbuterol of increasing both degradation and synthesis is unlike that reported in the literature for animals receiving protein when, in general, synthesis is unchanged and degradation reduced. This could be due to a different effect of clenbuterol in the N-free state, or to unchanged effects on protein pools other than muscle whose relative contribution to protein metabolism is different in the N-free state.
We have reported (Hovel1 et al. 1989 ) that the P,-adrenergic agonist clenbuterol reduced the endogenous nitrogen loss of sheep. That experiment was based on the hypothesis that the increase in N retention caused by the P,-agonists in animals given dietary protein is mediated by a decrease in body protein degradation Buttery & Dawson, 1987) . We had, therefore, reasoned that the /3,-agonists might reduce the endogenous N loss of animals given energy, but no protein, and found that clenbuterol did significantly reduce endogenous N losses. Clearly, such an effect could be mediated by the drug modifying either protein synthesis, or degradation, or both, with the net effect that a reduced amount of amino acid would be lost to oxidation. The objective of the work to be reported here was to extend our observations on the effect of clenbuterol on basal N loss to measurements of protein turnover.
M A T E R I A L S A N D METHODS

Treatments and design
Seven measurements were made of the daily endogenous N loss (UN,) during a 12 d period in six sheep (one sheep measured twice) given energy as an infusion of volatile fatty acids (VFA) into the rumen, but no protein (N-free period). The 12 d N-free period was divided into two 6 d subperiods either with or without the abomasal infusion of clenbuterol (6 10 pg/kg per d). On the last day of each 6 d subperiod, protein turnover was estimated from the irreversible loss rate of ~- [4,5-~H] leucine given by jugular infusion. For three of the Blood samples were prepared for analysis by precipitation of the protein by the addition of sulphosalicylic acid to a final concentration of 70 g/1 and analysed for amino acids as described by Lobley et al. (1980) .
Leucine kinetics and protein turnover
On the last day of each 6 d subperiod each animal was given ~- [4,5-~H] leucine (1 Ci/mmol ; Amersham International plc, Amersham, Bucks.) by jugular infusion. The leucine was diluted with sterile physiological saline to a final activity of 2.5 pCi/g, and infused at a rate of 20 g/h for up to 7.5 h. Six blood samples (10 ml) were taken from the other jugular catheter at 0.5 h intervals during the last 2.5 h of infusion, immediately transferred into chilled heparinized tubes containing 2.0 pmol L-norleucine, and stored for up to 1 h in a refrigerator before preparation for analysis.
The specific radioactivity (SRA) of each set of plasma samples was plotted v. time to check that a satisfactory plateau SRA had been attained. Total body protein synthesis was calculated from the apparent irreversible loss (flux ; Q) of blood-free leucine with the assumption that this loss occurred only by incorporation into body protein and by catabolism. Recycling was assumed not to occur during the 7.5 h infusion.
Q was calculated as: infusion rate (,uCi/h) SRA blood free-leucine (,uCi/mmol) ' Q ( m o l / h ) = Q was converted to g protein-N/d by multiplying by the factor 7.92 (from (24 x 13 1)/(0.635 x lo3 x 625)) as discussed by Reeds et al. (1980) , but with the modification that the average leucine content (g/g protein) in sheep body protein was taken as 0.0635 (D. S. Brown and E. Storm, unpublished results).
Protein synthesis (S) was calculated as:
Amino acid oxidation (plus other N losses from the animal due to protein catabolism; E), was taken to be UN, on the day of measurement, less the N of creatinine, purine derivatives and an allowance for pyrimidine catabolism. Purine-N was calculated from purine derivative-N (hypoxanthine, xanthine, uric acid and allantoin) by correction for the initial hydrolysis of the purine. Pyrimidine-N was assumed to be half purine-N. The total purine-and pyrimidine-N was thus calculated by multiplying purine derivative-N excretion by the factor 1.88.
Statistical analysis
Animals were treated as replicates for analysis of variance. The second and separate measurement made with one animal (sheep D) was also treated as an independent observation, giving a total of seven measurements for the control and clenbuterol treatments, and a within-animal comparison. Consecutive measurements made within an animal and within a treatment subperiod (e.g. daily N balance or six half-hourly plasma samples) were deemed not to be independent, and the analysis of variance was carried out on the averaged within-animal values. Where the analysis was for the effect of different days, then the observations on each animal within 1 d were deemed to be independent, and were analysed as such. The statistical package GENSTAT 5 (Lawes Agricultural Trust, Rothamsted Experimental Station) was used to process the values. Significance was tested by Student's two-tailed test. The variance (s.flux) of a single measurement of protein flux was calculated from the variance (s.SRA) of the plateau values for plasma leucine SRA (from equation 1 above when 'I' was the infusion rate) as: s.flux = (I2 x s.SRA)/SRA4 (Kendell & Stuart, 1963) . f Purine derivatives (xanthine, hypoxanthine, uric acid and allantoin).
0 Sum of urea-, ammonia-, creatinine-and purine derivative-N.
SED, standard error of difference between means; W, live weight; ME, metabolizable energy.
R E S U L T S
Animal healrh and management of infusion No major health problems occurred. When the drug was introduced, a slight muscle tremor was observed initially, but not the tachycardia we have observed with higher doses (Herbert et al. 1985) . Animal D had mild haematuria when clenbuterol was given. Since we have observed mild haematuria on other occasions with the infused animals, we do not believe it to have been associated with clenbuterol treatment. She was repleted with a casein infusion for 3 weeks, and then measurements were repeated. On both occasions animal D exhibited a large live-weight loss which could only be explained as water, and presumably as a fluctuation in the gastrointestinal tract pool size (the N loss was not abnormal). With the exception of animal D, weight losses over the 12 d of the experiment were 0.5 kg or less. The UN, of sheep D was very similar for the two measurements with clenbuterol. The two turnover measurements with animal D were rather different, but not abnormal in the context of the values obtained with the other animals. Therefore, the values from both measurements of turnover and N excretion made with this animal have been included in the results presented.
N excretion
UN, values are given in Table 1 . Excretion during the control periods ranged from 220 to .
I . E. INKSTER A N D OTHERS
Clenbuterol again tended to reduce UN,, but only by an average of 6% ( P < 010). However, clenbuterol did produce a significant ( P < 0.01) reduction in UN, on day 2, which when compared with the mean control was an average reduction of UN, of 22 YO. However, the effect was not maintained ( Table 2) . About 0.7 of the reduction in UN, was in the urea and ammonia fractions, and 0.3 in an unidentified fraction. There was no effect on creatinine or purine excretion, both of which remained relatively constant throughout the experimental periods ( Table 2) .
Unidentijied urinary N When the contributions of urea, ammonia, creatinine and purine derivatives to N excretion were summed and expressed as a proportion of the total urinary N measured by Kjeldahl digestion, about 20 YO of Kjeldahl N was unaccounted for. There was the suggestion that recovery was higher early in the period, and the values were examined in more detail. This showed a progressive decline in the N which could be accounted for as the N-free period progressed ( Table 3 ) which was independent of treatment. The relationship between the time and total N recovered was highly significant ( P < 0.001). The proportion of N accounted for ( Y ) declined by about one percentage unit daily ( Y = 87.6 -1.16 x day number, SE, 0.15).
Plasma amino acids
The mean plasma amino acid concentrations are given in Table 4 . There was no evidence of any effect of clenbuterol. There was the suggestion (not significant statistically), that concentrations tended to be lower in the second subperiod (ten from sixteen amino acids).
Protein turnover
The plateau specific activities were reasonably stable (SE on average was 2.9 YO of the mean).
Clenbuterol increased both protein flux and protein synthesis ( P < 0.05), with an average increase in protein flux of about 12 %. There was no relationship between protein flux and UN,, which was unchanged by treatment on the day of measurement (Table 5 ). The response of protein flux to clenbuterol infusion was variable, and the between-animal variance was significant ( P < 0.05, coefficient of variation 17 YO). Animal A showed no response to clenbuterol, and flux was unchanged. However animal A had shown a reduction in UN, on day 2 with clenbuterol (UN, on day 2 was 146 mg N/kg WU7' per d).
The difference between treatments when synthesis was expressed as a proportion of flux was not significant statistically (Table 5 ) but had to be real, since UN, and the constituents of UN, were unchanged (Tables 2 and 5 ). (The reduction of oxidation from 0.08 of flux to 0.07 of flux represents a reduction of 12%.) DISCUSSION 
N excretion
The 6 YO reduction of UN, with clenbuterol was less then the 14 % reduction ( P < 0.05) we reported previously (Hovell et al. 1989) . As in our earlier report, the effect was very variable between animals, the change in UN, ranged from a reduction of 18 YO to an increase of 2 %. We had also reported previously (Hovell et al. 1989 ) a relationship between AUN, ( Y ) and UN, ( X ) . No such relationship was apparent here ( Y = 83-0.32 X , ~~~0 . 6 9 , r0.42). The greater initial effect on the reduction of UN, is in agreement with our earlier finding (Hovell et al. 1989) . The mean creatinine excretion of 51-6 (SD 5.2) mg/kg Wn" per d compares well with those of 49-3 (SII 2.9) mg/kg Wn 75 per d and 53.4 (SD 4.8) mg/kg W" 75 per d obtained by Hovell et al. (1987 Hovell et al. ( , 1989 ) from N-free infused wethers and ewes. The mean
C L E N B U T E R O L A N D BASAL P R O T E I N T U R N O V E R I N SHEEP
endogenous excretion of purine derivatives (allantoin equivalent) of 27.5 (SD 3.4) mg/kg W0'75 per d compared well with the 23 (SD 7.7) mg/kg W075 per d reported by Fujihara et al. (1988) with slightly younger lambs.
VnidentGed urinary N
The use of urea plus ammonia excretion as an estimator of amino acid oxidation was shown by Reeds et al. (1980) to correlate well (r 098, slope 1.01) with oxidation determined from 14C0,. However, in the experiment reported here we were unable to account for all the urinary (Kjeldahl) N.
We have been unable to account for all the Kjeldahl N in the urine of animals on some other infusion experiments, particularly when fasted, or on N-free nutrition (unpublished observations). Repeated checks have been unable to identify any analytical error, and work is currently in progress to identify the missing component(s). About 0.3 of the reduction of UN, was in this unidentified component and it is probable that most of the unidentified N arose from protein catabolism, and that urea plus ammonia would thus underestimate the true loss to the animal of N arising from protein flux. Further analysis of urine samples from other experiments has suggested that certainly half the unaccountable N is amino-N (unpublished observations). Therefore, the loss of protein-N to the animal was taken as UN,, less the loss of N as creatinine and that due to purine and pyrimidine catabolism.
Basal protein turnover
The mean protein flux of 1646 (SE 056) g/kg W0.75 per d, measured during the control subperiod (Table 5) is of the same order as the mean values reported and cited by Krishnamurti & Janssens (1988) of from 8.0 to 20.4 g/kg W075 per d for wethers and dry ewes of between 42 and 67 kg live weight. All the values referred to previously were also determined by plasma amino acid flux (tyrosine or leucine) and, therefore, have that base in common. However, whereas the published values all relate to fed animals given protein and which were at or above protein equilibrium, our measurements were made when the animals were receiving energy but not protein, and should be representative of the basal state.
An advantage of the infused animals is that all N is excreted in the urine, since there is no rumen or hind-gut fermentation. Therefore, losses of amino-N to oxidation can be estimated from urine-N, which when corrected for creatinine and N estimated to come from purines and pyrimidines was 0-075 of flux (average of all values, Table 4 ). When estimated from urea plus ammonia alone, oxidation was estimated as 0.057 (overall mean) of flux. Thus, synthesis was, on average, between 0.943 and 0.925 of flux, but the general findings of the study reported here were unchanged since clenbuterol had no effect on the relative proportions of urine constituents.
Our In the experiment reported here the infusion of VFA was very steady, and the animals should have been stable. Even so there was a considerable between-animal variation, and the two measurements with sheep D gave total fluxes during the control subperiods of 364 and 224 g protein/d (SE of difference (SED) 9 g/d). (The SED of these two values which was based on SE of plateau SRA as described previously should include all sampling and analytical errors.) Although clenbuterol increased flux on both occasions, these two different values are presumably indicative of within-animal or methodological variation.
EfSect of clenbuterol
All the reports in the literature of the effect of P,-agonists on protein turnover in a range of species relate to animals which were already in a state of positive N accretion before the drug was given, and most relate to skeletal muscle. In their review, Buttery & Dawson (1 987) concluded that the improved N accretion resulting from treatment with P-agonists was due to reduced muscle degradation. This is supported by the observation of Wang & Beerman (1988) that cimaterol-treated lambs had a reduced level of muscular calciumdependent protease. However, there are also reports of an increased muscle protein synthesis in rats (Emergy et al. 1984 ) and mice (Pel1 et al. 1987) . In experiments in which measurements of whole-body protein metabolism have been made with fed sheep given clenbuterol, Bohorov et al. (1987) found no increase in tyrosine flux, while MacRae et al. (1988) who measured leucine flux at 4, 11 and 18 d after initiating treatment, found no increase in oxidation corrected leucine flux (i.e. synthesis) at 4 and 18 d, but did find an increase at 11 d. Both authors concluded that degradation was reduced in all periods and was the cause of the increased N retention. In the experiment reported here, in which energy but no protein was supplied, both synthesis and degradation were increased, whereas overall N status relative to the control was unchanged.
Our measurement of protein turnover was made on the sixth day of treatment with the drug, a factor which may have been important, for as the work reported here and previously (Hovel1 et al. 1989 ) demonstrated, the initial reduction in N loss when clenbuterol and cimaterol were given was not maintained. Thus, the effect on turnover may have been different on day 2. There are other examples of time after treatment affecting the effect of /3-agonists. We have shown in this Institute (Herbert et al. 1985; Brockway et al. 1987 ) that clenbuterol caused a considerable tachycardia and slight increase in rectal temperature in sheep when given at 1.5 mg/d, but that these effects only lasted for about 30 h, whereas the effect on N accretion persisted. MacRae el al.
(1 988) found with normally fed sheep a rapid (and variable) increase in energy expenditure which declined over 20 d, whereas the effect on N accretion was maintained and Maltin ef al. (1987) found a timerelated effect in the way in which enhanced accretion in denervated muscle was mediated.
The response within a tissue can also differ between different muscles and muscle fibre types (Maltin et al. 1986 (Maltin et al. , 1987 Beerman et al. 1987; Kim et al. 1987) . One of the interesting features of these drugs is their efiect on increasing N accretion through reduced protein degradation while also increasing general energy expenditure (see Buttery & Dawson 1987; Williams, 1987) presumably due to an increased flux of other metabolic cycles. In this context the increased protein flux observed in the experiment reported here is consistent with a generally enhanced rate of metabolic activity and substrate cycling.
It is not certain that the effect on muscle protein accretion is due to a specific P-agonist effect, for Reeds et al. (1988) have shown in rats that the /?-antagonists propranolol and atenolol blocked the effect of clenbuterol on energy expenditure (thought to be 8-mediated), but not the effect on increasing N accretion. However mediated, the effects of P-agonists on enhancing N accretion appear to be specific to muscle ). Therefore, it could be that the effect reported here on increasing protein flux during N-free nutrition demonstrated a different response to clenbuterol within specific tissues (e.g. muscle) from that of animals receiving exogenous protein. Alternatively it could have reflected the activities of, and effect on, other protein pools whose response to clenbuterol is different from that of muscle. Examples are the gastrointestinal tract, and the liver, whose greater metabolic activity make a greater contribution to whole-body protein flux than muscle. Thus, the sum of synthesis due to the liver, gastrointestinal tract and skin of cattle and sheep was reported to be 0.4 to 0.6 of whole-body synthesis, whereas that of skeletal muscle was 0.2 to 0.3 of whole-body synthesis Davis et al. 1981 ; Attaix et al. 1988) . In the N-free state, the relative contribution of the skin and body organs is greater, for McNurlan et al. (1982) showed the fractional synthesis rate of protein in the liver and jejunal mucosa of rats after 9 d N-free nutrition to be reduced to about 0.8 of that of the fed controls, while that of gastrocnemius muscle was reduced to about 0.2 of that of the controls.
A possible interpretation of the effect of clenbuterol increasing whole-body protein flux in the experiment reported here could be a /3-agonist stimulation acting mainly on protein pools other than muscle, in a way comparable with the /3-agonist effect on general metabolism (i.e. increasing flux), whereas with animals receiving exogenous protein this is masked by the anabolic effect on skeletal muscle. In this context, the 'repartitioning' effect of clenbuterol and cimaterol on increasing the deposition of carcass protein (skeletal muscle), and not changing or even decreasing deposition in the non-carcass proteins of the organs and skin of protein-fed rats (Reeds et al. 1988; Sainz & Wolff, 1988) and calves (Williams, 1987) , may be of relevance.
Conclusion
The effects of clenbuterol are multifaceted and, therefore, appear complex. In the work reported here with sheep given energy but not protein, clenbuterol caused an initial fall in N loss (UN,). However, this change was not persistent, for UN, returned to normal within a few days. The apparent return to normality masked an increase in protein flux (synthesis and degradation) with no increase in oxidation. The magnitude of these effects was variable between animals, and there was no confirmation of an earlier observation that the change in UN, caused by the drug was related to UN, when no drug was given.
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